Rewiring the inflammatory microenvironment to reverse ovarian failure: Immunomodulatory implications of finerenone
Journal of Reproductive Immunology · 2026-06 · 175 · 104915
DOI: 10.1016/j.jri.2026.104915 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Reproductive Immunology, 2026-06. Verfasst von Kuan-Hao Tsui und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biopharmaceutical Sciences, Nationa…. Hauptthemen laut MEDLINE: Primary Ovarian Insufficiency, Inflammation, Naphthyridines, Mineralocorticoid Receptor Antagonists. Die Arbeit nennt 7 Literaturangaben. Gefördert von: Kaohsiung Veterans General Hospital, National Science and Technology Council.
Abstract (Originalsprache)
Recent evidence suggests that the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone restores folliculogenesis and fertility in premature ovarian insufficiency (POI) by reversing ovarian stromal fibrosis. While structural remodeling of the extracellular matrix (ECM) is a primary finding, this editorial highlights that chronic low-grade inflammation and immune dysregulation are fundamental drivers of fibrotic progression. We propose that the therapeutic success of finerenone reflects a critical "rewiring" of the inflammatory microenvironment. MR signaling in immune cells, such as macrophages and T lymphocytes, promotes proinflammatory phenotypes and the secretion of profibrotic mediators including TGF-β, IL-6, and TNF-α. By antagonizing MR, finerenone interrupts the self-reinforcing immune-fibrotic feedback loop, facilitating immunological recalibration toward a reparative state. This perspective positions the immune-fibrotic axis as a rational therapeutic target alongside traditional ECM remodeling. Future translational priorities should include detailed immune profiling and the integration of inflammatory biomarkers to refine clinical strategies. Ultimately, recognizing the inseparability of fibrosis and chronic inflammation will be essential for developing effective interventions to rescue organ function in POI and other inflammation-driven pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biopharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Electronic address: k…
- Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biopharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan; National Museum of Ma…
Förderung
- Kaohsiung Veterans General Hospital
- National Science and Technology Council
Zitieren
APA
Tsui, K. H., & Li, C. J. (2026). Rewiring the inflammatory microenvironment to reverse ovarian failure: Immunomodulatory implications of finerenone. Journal of Reproductive Immunology, 175, 104915. https://doi.org/10.1016/j.jri.2026.104915
Vancouver
Tsui KH, Li CJ. Rewiring the inflammatory microenvironment to reverse ovarian failure: Immunomodulatory implications of finerenone. Journal of Reproductive Immunology. 2026;175:104915. doi:10.1016/j.jri.2026.104915
BibTeX
@article{Tsui2026,
author = {Tsui, Kuan-Hao and Li, Chia-Jung},
title = {Rewiring the inflammatory microenvironment to reverse ovarian failure: Immunomodulatory implications of finerenone},
journal = {Journal of Reproductive Immunology},
year = {2026},
volume = {175},
pages = {104915},
doi = {10.1016/j.jri.2026.104915}
}
EUVIMED